Biocracked
**Approach: Conceptual metaphor. Palette: D, bold color field.**

A single clear glass of water sits on a saturated mustard-yellow backdrop, shot at a slight low three-quarter angle. A hand-held pen injector rests beside it, its body a matte white with a small electric green dial ring as the only green accent. Hard but clean studio light from the upper left throws a crisp, defined shadow across the yellow surface. Through the glass, the injector is refracted into two slightly offset images, suggesting a signal that is split and hard to read. The mood is calm, questioning and balanced, with no drama. The background is fully warm and bright, with no blue cast. The surface has a subtle paper-like texture. There is no text, no label and no face.
Metabolism

Apa Ozempic lan Mounjaro Nggawa Depresi? Temuan saka 20 Studi

Dr. Synapse · · 4 min read

Judhul Sing Ngejutake vs. Data

Sawetara taun kepungkur, laporan babagan owah-owahan suasana ati lan pikiran bunuh diri ing wong sing nggunakake obat GLP‑1 wiwit nyebar. Pengawas kesehatan ora lengah. European Medicines Agency (EMA) lan US Food and Drug Administration (FDA) loro‑loro nindakake review. Siji tinjauan sistematis anyar ing Rambam Maimonides Medical Journal nyawijikake bukti-bukti, lan asil paling penting iku nyenengake: bukti uji coba acak nuduhake ora ana peningkatan risiko suicidality, depresi, utawa kecemasan saka agonis reseptor GLP‑1 (kayata semaglutide) utawa tirzepatide.

Gambaran lengkapé ngandhut sawetara cathetan penting sing ora bisa diabaikan.

Apa Sing Ditindakake Peneliti

Para penulis nggolèki literatur ing PubMed/MEDLINE, Embase, Web of Science, lan Scopus nganti 15 Maret 2026, mung nggatekake studi ing basa Inggris kanggo wong diwasa umur 18 taun ke atas sing kena diabetes tipe 2 utawa obesitas. Padha manut standar PRISMA 2020, bebarengan karo ekstensi PRISMA‑S lan PRISMA‑Harms. Total 20 studi lan loro review regulator sing cocog karo kriteria dipilih.

Bukti dipérang dadi grup sing wis ditemtokake sadurunge:

  1. Riset acak (randomised trials)
  2. Studi observasional komparatif lan emulasi target‑trial
  3. Studi outlier tanpa pembanding aktif
  4. Analisis farmakovigilansi (pelaporan efek samping)
  5. Review regulator

Para penulis ngevaluasi bias nganggo piranti Cochrane RoB 2 lan ROBINS‑I, lan nyimpulake tingkat kapercayan kanthi GRADE. Padha negesake bedane antarane deteksi sinyal (ana anomali ing data) lan inferensi kausal (obat pancen nyebabake).

Temuan Pokok sing Bisa Dipindai

Bukti Acak: ora ana risiko tambahan

Bukti paling kuat asalé saka uji coba acak, kalebu loro meta‑analisis gedhe 2025 lan analisis gabungan pasca‑hoc saka semaglutide lan tirzepatide. Ora ana siji wae sing nuduhake peningkatan suicidality, depresi, utawa kecemasan.

Kohort Donya Nyata: ora ana peningkatan cetha

Studi kohort kanthi pembanding aktif saka Amerika Serikat, Skandinavia, lan Britania Raya uga ora nemokake kenaikan sing jelas sawise ngontrol faktor konfounding. Desain pembanding aktif nyocogake pangguna GLP‑1 karo wong sing nganggo obat diabetes utawa penurun bobot liya, dadi perbandingan luwih adil.

Sumber Sinyal Sing Ngeresahake

Studi pembanding pasif lan analisis disproportionalitas memang ngasilake sinyal. Miturut review, desain iki ora bisa misahake efek obat saka telung penjelasan liyane:

  • Risiko psikiatrik dhasar
  • Stres sing gegayutan karo obesitas
  • Bias pelaporan

Desain iki migunani kanggo ngangkat pitakon, nanging lemah kanggo mangsuli pitakon kasebut. Wong sing ngalami obesitas wis nduwé tingkat depresi lan kecemasan luwih dhuwur; mbandhingaké karo wong sing ora kena kondisi kuwi bisa nyebabake interpretasi sing keliru.

Regulator: ora ana hubungan kausal sak kelas

Kesimpulan EMA lan FDA, kaya sing diringkesaké déning penulis, ora ndhukung hubungan kausal sak kelas antarane GLP‑1 RAs lan pikiran utawa prilaku bunuh diri.

Printah Cilik: Kenapa Iki Dudu Kartu Putih

Para penulis nyimpulake manawa bukti ora ndhukung kenaikan klinis sing penting saka kerusakan neuropsikiatrik ing populasi sing dipelajari. Pilihan tembung iki disengaja, lan ana sawetara watesan:

  • Uji coba ngilangi wong kanthi penyakit psikiatrik. Review nyathet yèn kriteria eksklusi psikiatrik mbatesi umumé hasil. Wong sing paling kuwatir babagan efek mood asring dadi sing paling ora diwakili ing data acak.
  • Asil sing langka lan jangka panjang isih ora pasti. Pengawasan tetep dibutuhake.
  • Populasi mung obesitas ditandhani kanggo monitoring terus.
  • Pasien kanthi morbiditas psikiatrik substansial uga ditandhani kanggo pengawasan.
  • Data observasional ora bisa ngilangi konfounding sepenuhnya, sanajan nganggo metode modern.
  • Review winates mung kanggo studi ing basa Inggris lan wong diwasa kanthi diabetes tipe 2 utawa obesitas. Ora ngrembug bocah utawa kondisi liya.

Takeaway Praktis

Iki review keamanan obat resep, dudu studi suplemen. Ora diuji dosis utawa strategi wektu, mula ora nyedhiyakake pandhuan dosis utawa jadwal. Pandhuan saka dokter lan label produk tetep dadi sumber utama.

Apa sing didhukung bukti:

  • Yen sampeyan wong diwasa karo diabetes tipe 2 utawa obesitas, bukti saiki ora nuduhake yèn semaglutide utawa tirzepatide (bahan aktif ing Ozempic/Wegovy lan Mounjaro/Zepbound) ningkataké risiko depresi, kecemasan, utawa suicidality.
  • Owah‑owahan mood sajrone penurunan bobot sing cepet isih bisa kedadeyan amarga akèh sebab. Laporké tinimbang nganggep iku ora bahaya utawa disebabake obat.

Sapa sing kudu luwih ati‑ati:

  • Wong kanthi riwayat penyakit psikiatrik signifikan, amarga padha kurang diwakili ing uji coba. Review nyaranake pengawasan terus ing kelompok iki, ora larangan.
  • Wong sing nggunakake obat iki mung kanggo obesitas, populasi sing ditandhani kanggo monitoring luwih lanjut.

Sapa sing bisa ora nggunakake? Review ora nemokake grup apa wae sing kudu ngindhari obat iki amarga alesan neuropsikiatrik. Keputusan nggunakake obat GLP‑1 gumantung saka riwayat medis lengkap lan diskusi karo dokter.

Yen sampeyan ngrasakake mood rendah, kecemasan, utawa pikiran kanggo nyakiti diri, cepet hubungi penyedia layanan kesehatan. Ing AS, sampeyan bisa nelpon utawa SMS 988 kanggo Suicide & Crisis Lifeline. Aja mandheg utawa ngowahi obat dhewe tanpa saran medis.

Kesimpulan

Bukti paling terkontrol nuduhaké arah sing padha: ora ana peningkatan suicidality, depresi, utawa kecemasan, lan ora ana link kausal sing dikonfirmasi regulator. Sinyal sing medeni asalé saka desain studi sing ora bisa misahake efek obat saka risiko sing wis ana lan bias pelaporan. Pitakon sing isih ana yaiku kanggo pasien kanthi riwayat psikiatrik serius lan asil jangka panjang sing arang kelakon. Kanggo kuwi, jawaban sing jujur yaiku pengawasan kudu diterusake.

Artikel iki nyimpulake review sing wis diterbitake lan ora dadi saran medis.

Original study

Read the original research on pubmed.ncbi.nlm.nih.gov →

This article summarizes published research for general information. It is not medical advice.

DS

Written by

Dr. Synapse

Dr. Synapse writes for Biocracked: biohacking science, longevity & human performance.

Related Articles

Approach 3, the human outcome, in palette B, warm.

Low three-quarter rear angle, shot with a 50mm lens at shallow depth of field. A middle-aged person's forearm and hand grip a loaded barbell mid-deadlift, the tendons and the muscle of the forearm clearly defined, with chalk dust hanging in the air. Their face is out of frame. The setting is a plain home garage gym with a rubber floor and a rack softly blurred in the background. Low golden-hour sunlight comes through an open roll-up door and rakes across the skin and the knurled steel, casting long warm shadows. Amber, copper and honey tones dominate, with matte black plates for contrast. A tiny electric green silicone wristband or a small green pen injector resting on a nearby shelf adds a subtle accent. The mood is determined, quiet and hopeful.
metabolism

Bab Tirzepatide: Angkat Beban Nglindhungi 1,1 kg Massa Otot

BY REX MERIDIAN ·

Tirzepatide bisa ngilangi luwih saka 22 kg ing 40 minggu, nanging uga nyedhot jaringan otot lan nyuda kekuwatan. Siji uji coba acak karo 120 wong mriksa apa angkat beban telung kali seminggu isa nglindhungi otot. Penurunan lemak tetep podho, nanging grup sing ngangkat beban mung ilang kira‑kira 1,1 kg jaringan otot. Kekuwatan mudhun ing grup obat waé lan nambah ing grup sing ngangkat beban. Iki angka‑angka lan tegesé kanggo sing nganggo Mounjaro utawa Zepbound.

Approach: 3, the human outcome, here as an animal-science moment. Palette: C, natural.

An old female lab mouse with slightly greying, ruffled fur sits upright on a researcher's open gloved palm, photographed at eye level in a close side-on view with a shallow depth of field. Behind it, a softly blurred animal facility window pours in real morning daylight, giving the scene a pale green-grey and warm-wood setting. The nitrile glove is a vivid electric green (#00e676), the single saturated accent. The mouse's whiskers and pink ears catch the light, and the researcher's white coat sleeve is just visible. Tones are natural: skin, soft cream bedding, sage walls. The mood is calm, careful and quietly hopeful, and it conveys age and care rather than drama. The image has no text, no labels and no readable writing.
longevity

Bahan Aktif Ozempic Nambah Umur Tikus Tuwa: Kene Alasane

BY DR. SYNAPSE ·

Semaglutide, bahan aktif ing Ozempic lan Wegovy, nambah umur tikus betina tuwa ing riset anyar ing *Nature* saka UC Berkeley. Perawatan diwiwiti nalika umur 20 sasi lan niru akèh manfaat saka pembatasan kalori. Dibandhingake langsung, obat iki uga nuduhaké asil sing luwih apik tinimbang pembatasan kalori ing babagan motivasi eksplorasi, memori spasial, lan kontrol glukosa. Nanging iki mung riset tikus betina, tanpa pandhuan dosis kanggo manungsa.

Approach: Macro science, the human outcome angle through tissue. Palette: D, bold color field.

Extreme close-up of a cross-section of raw beef thigh muscle, used as a stand-in for human thigh tissue. It is shot straight on and slightly from above, on a saturated tomato-red seamless backdrop. Fine white fat marbling threads run through the dark red muscle fibers. On one half the marbling is dense and lacy, and on the other it is sparse and clean, so the contrast reads as a before and after. A thin, translucent calipers-style steel ruler lies along the edge, with no markings readable. Lighting is soft, directional studio light from the upper left, with crisp highlights on the glistening fibers and gentle warm shadows. A single small electric green surgical marker dot sits on the tissue. The mood is analytical, tense and uncertain, with shallow depth of field and sharp detail on the fat texture.
longevity

Semaglutide Dosis Tinggi lan Otot Paha: Apa sing Dituduhaké MRI

BY HELIX WARD ·

Analisis sub‑MRI anyar saka uji coba STEP UP nyinaoni pengaruh 72 minggu semaglutide dosis tinggi (7,2 mg) marang komposisi awak, kalebu otot paha. Lemak mudhun drastis, udakara 11 liter dibandhingake placebo, lan infiltrasi lemak ing otot paha uga turun sacara signifikan. Volume otot paha mudhun kira‑kira 1,1 liter, perubahan sing ora ngluwihi signifikansi statistik (p = 0,07) nanging interval kapercayan nuduhaké kecenderungan ilang. Amarga mung 55 peserta sing dipindai, lan mung enem ing grup placebo, plus keterlibatan Novo Nordisk, asil iki kudu dianggep sinyal, dudu kasunyatan final. Artikel iki nerangake apa sing bisa dituduhaké data, apa sing ora, lan kepiye cara njaga otot nalika nganggo GLP‑1.

**Approach:** Lab in action. **Palette:** Bold color field, mustard yellow.

A close, slightly high three-quarter view of a hand in a magenta-purple nitrile glove holding a clear 12-well cell culture plate. Each well is filled with salmon-pink culture medium. A multichannel pipette hovers over one well, with a single droplet caught just before it falls. The background is a seamless, saturated mustard-yellow surface and wall, with a soft shadow under the plate. Bright, even studio light comes from the upper left, giving crisp highlights on the plastic rims and a soft glow through the liquid. The depth of field is shallow, so the far wells blur gently. A tiny electric-green cap on a tube sits in the corner of the frame. The mood is calm, precise and curious, with a clean, graphic, editorial feel. No text or labels.
peptides

Semaglutide Ora Ngerusak Sel Otot Manungsa, Dadi Kok Otot Kethil?

BY DR. SYNAPSE ·

Apa semaglutide bener‑bener nyerang otot? Panaliten ing *GeroScience* ngaplikasikake semaglutide langsung marang sel otot primer manungsa sing wis tuwa lan kegemukan, lan sel‑sel mau ora kethil. Ora ana gen atrofik sing diaktifake, ora ana sinyal darurat sing ngganggu, malah GIP nambah kandel myotube sawise wolu dina. Semaglutide mung nyuda produksi ATP liwat glikolisis kanthi sithik, lan reseptor GLP‑1 mung sithik ditemokake. Asilé nuduhaké yèn mundhut massa otot luwih disebabake defisit kalori lan beban sing suda, dudu amarga semaglutide langsung ngrusak otot.

This page is available in